[Respiratory depression following controlled-release morphine sulfate tablets]

Area of Science:

• Pharmacology
• Pain Management
• Clinical Toxicology

Background:

• Controlled release morphine sulfate (MS Contin) is an oral analgesic for chronic severe pain.
• Opioid analgesics are commonly used for cancer pain management.
• Understanding the adverse effects of novel drug formulations is crucial.

Observation:

• A patient with severe neuralgia experienced respiratory depression after a single 20 mg dose of MS Contin.
• Respiratory depression is a potentially life-threatening side effect of opioid analgesics.
• The patient's respiratory function rapidly normalized after nalorphine chloride administration.

Findings:

• This case highlights respiratory depression as a significant adverse effect of MS Contin.
• The rapid reversal of respiratory depression by nalorphine chloride demonstrates its efficacy as an antidote.
• Even single doses of controlled release morphine sulfate can pose risks.

Implications:

• Clinicians should be vigilant for respiratory depression when prescribing MS Contin.
• Prompt recognition and management of opioid-induced respiratory depression are essential.
• This case underscores the importance of monitoring patients receiving novel opioid formulations.